Black Diamond Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 21

Employees

  • Stock Symbol
  • BDTX

Stock Symbol

  • Share Price
  • $1.38
  • (As of Thursday Closing)

Black Diamond Therapeutics General Information

Description

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Contact Information

Formerly Known As
Aset Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 245 First Street
  • 18th Floor
  • Cambridge, MA 02142
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 245 First Street
  • 18th Floor
  • Cambridge, MA 02142
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Black Diamond Therapeutics Stock Performance

As of 19-Nov-2026, Black Diamond Therapeutics’s stock price is $1.38. Its current market cap is $79.9M with 57.5M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.38 $1.43 $1.35 - $4.05 $79.9M 57.5M 698K -$0.77

Black Diamond Therapeutics Financials Summary

As of 30-Sep-2026, Black Diamond Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 14,764 22,616 31,409 26,881
Revenue 0 70,000 0 0
EBITDA (47,879) 18,631 (71,515) (83,929)
Net Income (44,069) 22,367 (69,676) (82,442)
Total Assets 115,561 143,010 122,640 158,567
Total Debt 16,036 18,781 22,186 25,298
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Black Diamond Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Black Diamond Therapeutics‘s full profile, request access.

Request a free trial

Black Diamond Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Black Diamond Therapeutics‘s full profile, request access.

Request a free trial

Black Diamond Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families
Drug Discovery
Cambridge, MA
21 As of 2026

San Diego, CA
 

Chengdu, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Black Diamond Therapeutics Competitors (45)

One of Black Diamond Therapeutics’s 45 competitors is Crinetics Pharmaceuticals, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Crinetics Pharmaceuticals Formerly VC-backed San Diego, CA
Polaris Group (Drug Discovery) Formerly PE-Backed Chengdu, China
Sagimet Biosciences Formerly VC-backed Foster City, CA
Oncorus Formerly VC-backed Andover, MA
Xenetic Biosciences Corporation Framingham, MA
You’re viewing 5 of 45 competitors. Get the full list »

Black Diamond Therapeutics Patents

Black Diamond Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026064728-A1 Method of treating cancers with alkyne substituted quinazoline derivatives Pending 23-Sep-2024
WO-2026039338-A1 Compositions comprising alkyne substituted quinazoline derivatives and related uses Pending 12-Aug-2024
WO-2025226822-A2 Forms and salts of 6-aza-quinoline derivatives and related uses Pending 24-Apr-2024
AU-2025263379-A1 Polyforms and salts of a 1,6-naphthyridine compound and their use for the treatment of cancer Pending 24-Apr-2024
WO-2025226822-A3 Polyforms and salts of a 1,6-naphthyridine compound and their use for the treatment of cancer Pending 24-Apr-2024 A61P35/00
To view Black Diamond Therapeutics’s complete patent history, request access »

Black Diamond Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Black Diamond Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

38.58 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Black Diamond Therapeutics’s complete esg history, request access »

Black Diamond Therapeutics Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Black Diamond Therapeutics Security Corporation Cambridge, MA 2019

Black Diamond Therapeutics FAQs

  • When was Black Diamond Therapeutics founded?

    Black Diamond Therapeutics was founded in 2014.

  • Where is Black Diamond Therapeutics headquartered?

    Black Diamond Therapeutics is headquartered in Cambridge, MA.

  • What is the size of Black Diamond Therapeutics?

    Black Diamond Therapeutics has 21 total employees.

  • What industry is Black Diamond Therapeutics in?

    Black Diamond Therapeutics’s primary industry is Drug Discovery.

  • Is Black Diamond Therapeutics a private or public company?

    Black Diamond Therapeutics is a Public company.

  • What is Black Diamond Therapeutics’s stock symbol?

    The ticker symbol for Black Diamond Therapeutics is BDTX.

  • What is the current stock price of Black Diamond Therapeutics?

    As of 19-Nov-2026 the stock price of Black Diamond Therapeutics is $1.38.

  • What is the current market cap of Black Diamond Therapeutics?

    The current market capitalization of Black Diamond Therapeutics is $79.9M.

  • Who are Black Diamond Therapeutics’s competitors?

    Crinetics Pharmaceuticals, Polaris Group (Drug Discovery), Sagimet Biosciences, Oncorus, and Xenetic Biosciences are some of the 45 competitors of Black Diamond Therapeutics.

  • What is Black Diamond Therapeutics’s annual earnings per share (EPS)?

    Black Diamond Therapeutics’s EPS for 12 months was -$0.77.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process